[1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists

Details [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists

2006-07-18

2006-07-18

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07078408

ABSTRACT:
Compounds having the structural formula Iwherein:n is 0, 1, 2 or 3;A is C(R1) or N;R1and R1aare H, (C1–C6)-alkyl, halo, CN or —CF3;X is —C(O)—, —O—, —SO0-2—, or optionally substituted methylene, imino, arylene or heteroaryldiyl;Y is —O—, —SO0-2—, or optionally substituted arylene, heteroaryldiyl, or nitrogen-containing heterocycloalkyl, or with certain provisos, a bond;R is optionally substituted-aryl or heteroaryl; andR2is optionally substituted-aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R2—Y is a fused piperidinyl, substituted piperazinyl or substituted piperidinyl;their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations

REFERENCES:
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 6222035 (2001-04-01), Tsumuki et al.
patent: 6630475 (2003-10-01), Neustadt et al.
patent: 6653315 (2003-11-01), Tulshian et al.
patent: 6875772 (2005-04-01), Neustadt et al.
patent: 0 976 753 (2000-02-01), None
patent: 1 116 722 (2001-07-01), None
patent: WO 95/01356 (1995-01-01), None
patent: WO 97/05138 (1997-02-01), None
patent: WO98/52568 (1998-11-01), None
patent: WO 99/43678 (1999-09-01), None
patent: WO 01/17999 (2001-03-01), None
patent: WO 01/92264 (2001-12-01), None
Ungerstedt et al,Brain Research, 24 (1970), 485-493.
Ungerstedt,Eur. J. Pharmacol., 5 (1968), 107-110.
Derwent Abstract of WO 99/43678.
Patent Abstracts of Japan, vol. 2, No. 6 (2002), publication No. 2002037787, Feb. 6, 2002.
Wermuth, “The Practice of Medicinal Chemistry,” (Academic Press, 1996), p. 203-237.
“Parkinson's Treatments: L-dopa” <http://www.macalester.edu/-psych/whathap/UBNRP/parkinsons/Idopa.html>.
“Understanding Parkinson'Disease” http://www.stalevo.com/info/simplystated/parkinson—disease—treatment.jsp?checked=y.
Vu et al,J. Med. Chem., 47 (2004) p. 4201-4299.
Palmer,Biochemsitry, 36 (4) (1997) p. 832-8.
Lazarino,Br. J. Pharmacol., 109 (4) (1993) p. 1110-1119.
Kanda et al,Eur. J. Pharmacol., 256 (1994) p. 263-268.
Shiozaki et al,Psychopharmacol., 147 (1999) p. 90-95.

Affiliated with

Also associated with

Rating

[1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3538984